2022-07-06-世界卫生组织-Immunization_Portugal_2022_country_profile_16页_339kb

Portugal Immunization Coverage Summary (WHO and UNICEF, 2022 Revision)

Background

WHO and UNICEF estimate national immunization coverage through annual review of country reports, surveys, and empirical data. Estimates began in 2015 for specific vaccines like IPV and are based on varying data sources with no probability models. Key vaccines covered include BCG, DTP3, Pol3, and others. Data reliability is assessed via a Grade of Confidence (GoC) system, indicating empirical support but not data quality.

Key Immunization Coverage Overview

WHO and UNICEF estimates for Portugal's immunization coverage are based on data from sources such as administrative records, surveys, and official reports as of July 7, 2022. Coverage generally remains high and stable for most vaccines, though some years lack high-quality empirical data.

Grade of Confidence (GoC) System

• ••• (High): Supported by multiple high-quality sources (e.g., survey data, recalculated denominators).
• •• (Medium): Based on at least one data source with no conflicting evidence.
• • (Low): Limited or disputed data sources, carrying higher uncertainty. All estimates should be used cautiously.

Specific Vaccine Coverage Trends (Based on 2010-2021 Data)

• BCG: Coverage typically ranges from 96% to 99% before 2021, but 2021 estimate shows variability; GoC often R+ (medium support).
• DTP3 (Diphtheria/Tetanus/Pertussis): Coverage consistently >95% (e.g., 97-99%), with 2021 estimates based on extrapolation; GoC is frequently "No accepted empirical data" for recent years.
• Pol3 (Polio): Coverage is highly stable at 97-99%; 2021 estimates are reliable with GoC=R+.
• MCV1/MCV2 (Measles Containing Vaccine): MCV1 ranges from 96-99%, MCV2 from 95-96%; estimates show high consistency, but some years lack surveys; GoC=R+ for many.
• IPV1 (Inactivated Polio Vaccine): Introduced in 2015; coverage estimates start then, often relying on DTP1; GoC generally "No empirical data" due to lack of dedicated surveys.
• Overall trends indicate excellent coverage for preventable diseases, with minimal fluctuations, but caution is needed due to data source reliance.

Data Limitations and Recommendations

Estimates use various data sources with potential biases, and GoC reflects empirical support rather than quality. Surveys are recommended for validation where missing. Next revision available in July 2023. For detailed data, refer to the provided links.